Insilico Medicine closes $37mm Series B round
Executive Summary
Insilico Medicine Inc. raised $37mm through its Series B round led by Qiming Ventures and including Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners and Series A investors. The company is using artificial intelligence platforms for drug discovery and will put the Series B proceeds towards commercialization of its validated generative chemistry and target identification technology. Potential therapy areas include cancer, fibrosis, nonalcoholic steatohepatitis, immune conditions, and CNS diseases.
Deal Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice